Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
NCT06730750Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2025
- Primary completion
- Sep 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label trial of BMS-986490 in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 1 more (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with Adverse Events, Number of participants with Serious Adverse Events and 3 more. Started Feb 2025; status: active, not recruiting.
02
Drugs
BMS-986490
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT06730750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730750.